Movement disorders are neurological disorders that mar speed, quality, fluency, and thus reduce the sufferer’s ease of movement. Those suffering from movement disorders often show abnormal fluency or speed of movements, called dyskinesia, or they may show excessive or involuntary movement, called hyperkinesia, or slowed or absent voluntary movement, called hypokinesia. Some of the commonly seen movement disorders are ataxia, dystonia, multiple system atrophies, Parkinson’s disease, restless leg syndrome (RLS), Tourette syndrome, and Wilson’s disease, among others. Over the years, scientists and doctors have observed a consistent relationship between dementia and movement disorders. However, their particular pattern of correlation is unique to every case, or it may not even exist.
Persistence Market Research’s recently published report on the global treatment for syndromes of dementia and movement disorders market provides an extensive assessment of the market, evaluating the growth prospects for a six-year forecast period 2014-2020. It comprises key trends and restraints impacting the overall market growth, recent trends and upcoming opportunities, market segmentation, regional analysis, and key players vying for the leading market position.
Starting with an overview of the global treatment for syndromes of dementia and movement disorders market, the report further analyzes the factors that positively and negatively influence the demand for treatment for syndromes of dementia and movement disorders. It provides deep insights into why food retail is expected to gain higher traction in developing markets, and what are the deterring factors that will affect the market growth over the forecast period, 2014-2020. Latest trends and opportunities sections of the report highlight the most valuable data to recognize the most lucrative opportunities for the market growth.
Segmentation of the global market for treatment for syndromes of dementia and movement disorders focuses on various treatment for syndromes of dementia and movement disorders. The geographical analysis of the global market examines the market status in key regions viz. Europe, North America, Asia and Rest of the World. The market report elaborates on why developing markets may witness robust growth and outpace the long-term leader during the forecast period. The next section of the report includes all the leading companies competing in the market for a leading position. Strong presence of global players and established local brands makes the landscape extremely competitive. The report throws light on the growth pattern, revenues, and upcoming opportunities for each of the players.
To deduce the global treatment for syndromes of dementia and movement disorders market size, the report considers various aspects based on secondary research. Furthermore, key data points such as region-wise split and market split by drug used for treatment progressive dementia and movement disorders and qualitative inputs from primary respondents have been incorporated to arrive at appropriate market estimates. The forecast presented in the report assesses the total revenue generated and expected revenue contribution in the global treatment for syndromes of dementia and movement disorders market. The report begins with sizing the market in terms of value and volume for the base year, which forms the basis for forecasting how the market is anticipated to take shape in the near future. Given the characteristics of the market, gathered data is triangulated via different analysis based on supply side and demand side drivers and other key dynamics of the global treatment for syndromes of dementia and movement disorders market. To develop the market forecast, Persistence Market Research has also conducted a factor analysis to understand the impact of various forces/factors on the target market. The report provides forecasts not only in terms of CAGR but also presents a detailed analysis based on key parameters such as Year-on-Year (Y-o-Y) growth to understand market predictability and to identify the right opportunities.
Another key feature of this report is an analysis of the global treatment for syndromes of dementia and movement disorders market and the corresponding revenue forecast in terms of absolute dollar opportunity, usually overlooked while forecasting the market. However, absolute dollar opportunity is critical in assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales perspective in the global treatment for syndromes of dementia and movement disorders market. Further, to understand key segments in terms of their growth and overall global treatment for syndromes of dementia and movement disorders market performance, Persistence Market Research has developed a market attractiveness index to help providers identify existing market opportunities in the global treatment for syndromes of dementia and movement disorders market.
Dementia is a broad category of mental illnesses, which, in the long run, leads to degeneration of the ability to think and remember in an individual. Despite the advancements in science and medicine, the causes of dementia haven’t yet been identified. Consequently, the disease is only treated symptomatically. Nonetheless, in many cases movement disorders such as Parkinson’s are known to be a catalyst to dementia. Research shows that about 80% of people with Parkinson’s or other movement disorders develop cognitive defects. The global market for treatment for syndromes of dementia and movement disorders in 2014 recorded revenues worth US$ 12,859.8 million, which are expected to raise up to US$ 21,154.8 million by the end of 2020. Over the forecast period 2014-2020, the global food retail market will expand at a healthy CAGR of 8.6%.
Key Market Dynamics
Although, dementia doesn’t just affect the patients, but also those around him/her. As the number of old people is increasing across the globe, the number of cases registered for dementia are also on the rise. Against this backdrop, the market for treating patients with dementia and movement disorders is gaining an impetus. As the disease is overwhelming for caretakers, medical facilities across the globe are looking at solutions such as home care services, adult day care services, psychological therapies, medication, and medical devices for last stage dementia patients, such as gastronomy feeding tubes. Another important segment of treatment for dementia and movement disorders is seen in the growth of palliative care units.
Though a lot of effort is being made to ease the troubles of those suffering from dementia and movement disorders, the strict nature of regulatory framework, red tape in approval system of drugs, paucity of funds for research and development, and poor therapeutic management methods are causing major hurdles for this market. Additionally, most drugs to treat the disease fail Phase III of testing, making the efforts seem in vain and bringing the problem of treating these conditions back to square one.
The global market for treatment for syndromes of dementia and movement disorders is categorized on the basis of drugs used for treatment of progressive dementia, movement disorders and progressive dementia with certain other neurological abnormalities. Among these, the segment of drugs used in treatment of progressive dementia is segmented as drugs for progressive dementia and diseases based therapeutics in progressive dementia. Meanwhile, the segment of drugs used with other neurological abnormalities to treat progressive dementia is categorized into drugs with other neurological abnormalities for progressive dementia and disease based therapeutics with other neurological abnormalities under progressive dementia. Also the segment of drugs used for treating movement disorders is segmented as drugs for movement disorders and diseases based therapeutics in movement disorders.
Based on geographical region, the global market for treatment for syndromes of dementia and movement disorders is segmented into Europe, North America, APAC and Rest of the World. In the global market for treatment for syndromes of dementia and movement disorders, the North America region is expected to remain dominant owing to growing aging population and rising incidences related to neurodegenerative diseases. Also in next six years, the Asia region is anticipated to expand at higher growth rates in the global market for treatment for syndromes of dementia and movement disorders.
Key Market Players
Major companies operating in the global market for treatment for syndromes of dementia and movement disorders include Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Valeant Pharmaceutical International, and Pfizer, among others.
Some of the major players in the treatment for syndromes of dementia and movement disorders market:
These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability, and financial overview.